Joshua Richter, MD, FACP
@JoshuaRichterMD
Associate Professor of Medicine, Hematology, and Medical Oncology Center of Excellence for Multiple Myeloma @TischCancer @IcahnMountSinai @MountSinaiNYC
2 negative odac votes for blenrep. I missed the discussion but this drug has a role in myeloma. Hoping the fda still approves it. #mmsm
There's still time to register for gotoper.com/courses/live-m… @IcahnMountSinai faculty: John Mascarenhas, @JoshuaBrodyMD, @JoshuaRichterMD
📌 Real-world data sheds light on teclistamab use in multiple myeloma patients with renal impairment (RI)—a group often excluded from trials. In 384 patients, 21% had RI (CrCl <40 mL/min), including those on dialysis. 💡 Despite higher cytopenias, efficacy (ORR 52%) and safety…
Meet the panel: @AjaiChari, @AjayNookaMD, @MMBaljevicMD, @GKaurMD, and @anupamakumar05—watch as they explore how #Teclistamab and #Elranatamab compare in relapsed/refractory #MultipleMyeloma. In Episode 3 of Around the Practice, they break down efficacy, safety, and clinical…
The State of Blenrep: What Patients Should Know - MMRF. New PDUFA for blenrep. October 23. Fingers crossed. #mmsm themmrf.org/mmrf-blogs/the…
Now let’s see what happens here in the US. PDUFA date is today. Blenrep (belantamab mafodotin) combinations approved in Canada for the treatment of relapsed/refractory multiple myeloma #mmsm @NBahlis ca.finance.yahoo.com/news/blenrep-b…
From @AdamKittai and colleagues: International consensus statement on diagnosis, evaluation, and research of Richter transformation: the ERIC recommendations ashpublications.org/blood/article/…
Brilliance 👇👇
Program Director’s Note - Personal Statement Pitfalls A #ProgramDirectorsNote to my @TradIMYale residents now that fellowship applications are in. My @YaleIMed are great writers, but there are always pitfalls to avoid. open.substack.com/pub/siegelmark…
The FDA recently approved linvoseltamab for the treatment of relapsed or refractory multiple #myeloma. Hear @JoshuaRichterMD, of @TischCancer, talk about results of the LINKER-MM1 study that led to FDA approval. ➡️ buff.ly/2gLMfrb
agree! always a partnership with pt. FDA cannot decide based on presumed negligence of docs. Many of our meds are difficult. Expertise is important. Wouldn't use this in a pilot or neurosurgeon... every patient unique. But withholding an active/usable drug is counterproductive.
Two specific situations where belantamab can have a major impact are 1) Relapsed high tumor burden myeloma that is refractory to other myeloma drugs and where CART or bispeicifics will be too risky. Here even a few doses of belantamab to control myeloma can open up other…
What do extended MonumenTAL-1 findings mean for real-world treatment in Relapsed-Refractory Multiple Myeloma? In Part 2 of Around the Practice, experts, @AjaiChari, @AjayNookaMD, @MMBaljevicMD, @GKaurMD, and @anupamakumar05 discuss: • Identifying appropriate candidates for…
Now in @BCD_AACR: Largest RW experience with teclistamab ever! Of 509 🇺🇸 pts (88% TEC-1 🙅🏽), ORR 53% and ≥VGPR 45%. mDOR 16 mo if ≥VGPR. I like ≥VGPR focus, i.e. #MMsm M-spike not 0 yet. When occurs, DOR similar for BCMA-naive vs exposed >9 mo ago! aacrjournals.org/bloodcancerdis…
Drake when he finds out that even the consolidation has twice-weekly bortezomib and dex 40 mg weekly…
How Frequently Are Bone Marrow Biopsies Needed in #Myeloma? A Patient’s Guide youtu.be/LdbtHC-CszM?fe… #mmsm @JoshuaRichterMD
👇👇👇 Absolutely. T cell redirection is not classical chemotherapy !!!
One of the issues with "first generation" bispecific TCE in MM is that doses and schedules were developed on the assumption that levels have to be > EC90 all the time. Empirically we are learning that is not the case, less is actually safer and may be better.
Endless gratitude and joy having the opportunity to share knowledge with myeloma doctors from France, Japan and China. Nothing will stop us from finding the cure ! #mmsm
onclive.com/view/anito-cel… via @onclive @GKaurMD presented findings at #EHA2025 #MultipleMyeloma @IcahnMountSinai
Just published! Updated EHA-EMN guidelines for the diagnosis, treatment and follow-up of #MultipleMyeloma! #mmsm nature.com/articles/s4157… @EHA_Hematology @EMN_EuMMnet @UoATherapeutics